Bioregnum Opinion Column by John Carroll This morning biotech Dragonfly put out word that Bristol Myers Squibb has handed back all rights to its IL-12 clinical-stage drug after spending $650 million to advance it into the clinic.
The news arrives amid a turbulent R&D stage...
